ASX:ATX

Amplia Therapeutics Limited · ASX · Healthcare · AUD · FY for 2026

Figures on this page computed 2026-11-08 12:43 UTC

Last close

n/aAUD

Market data

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
AUD
- computed
- Computed from the filing for 2026
-68.0%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
AUD
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
- Computed from the filing for 2026
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
AUD
- Computed from the filing for 2026
- Computed from the filing for 2026
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
AUD
- Computed from the filing for 2026
- Computed from the filing for 2026
0.01Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
AUD
- Computed from the filing for 2026
- Computed from the filing for 2026
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
AUD
- computed

Growth is the furthest below its sector's middle: 0.36 against 0.46 on the market's range.

Margins: n/aWe do not hold this figure for this company, so there is nothing to place.
What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

n/a

1.66x

1.89x

0.43x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2026

Computed2026

Computed2026

Computed2026

Market datan/a

Each against its own average

3 of 5 read

Except where said otherwise: Computed from the filing for 2026

Salesn/a
Its own average over 9 years, 1.7M.
Profit1.66x
Its own average over 10 years, -4.6M.
Free cash flow1.89x
Its own average over 10 years, -4.6M.
Debt0.43x
Its own average over 8 years, 792.9K.
Pricen/a
Its own average over 0 years. Market data

Free cash flow is furthest from its own average, at 1.89 times.

Profit is 1.66 times its own 10-year average; Free cash flow is 1.89 times its own 10-year average; Debt is 0.43 times its own 8-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2026

Sales against its own 9-year averagen/a
Not held.
Source
computed
Statement
income
Fiscal year
2026
Reported in
AUD
Profit against its own 10-year average1.66
Source
computed
Statement
income
Fiscal year
2026
Reported in
AUD
Free cash flow against its own 10-year average1.89
Source
computed
Statement
income
Fiscal year
2026
Reported in
AUD
Debt against its own 8-year average0.43
Source
computed
Statement
income
Fiscal year
2026
Reported in
AUD
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
AUD